Spots Global Cancer Trial Database for Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

Official Title: A Pilot Study of Beta-Blockers in Patients With Advanced Cancer

Study ID: NCT02013492

Conditions

Male Breast Cancer

Recurrent Melanoma

Stage IV Breast Cancer

Stage IV Melanoma

Stage IV Ovarian Epithelial Cancer

Stage IV Ovarian Germ Cell Tumor

Unspecified Adult Solid Tumor, Protocol Specific

Hepatocellular Carcinoma

Interventions

propranolol hydrochloride

Correlative Studies

Study Description

Brief Summary: This pilot trial studies propranolol hydrochloride in treating patients with locally recurrent or metastatic solid tumors that cannot be removed by surgery. Propranolol hydrochloride may slow the growth of tumor cells by blocking the use of hormones by the tumor cells.

Detailed Description: PRIMARY OBJECTIVES: I. To determine the feasibility and tolerability of beta-adrenergic blockade in patients with metastatic or locally advanced cancer. II. To determine the effects of beta-adrenergic blockade on the tumor microenvironment and host immune system via a series of correlative laboratory studies using cancer tumor tissue and peripheral blood mononuclear cells from the study patients. SECONDARY OBJECTIVES: I. Evaluate the effects of beta-adrenergic blockade on progression-free survival and overall survival. OUTLINE: Patients receive propranolol hydrochloride orally (PO) twice daily (BID) for 4 months in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up every 3 months for up to 1 year.